PDCD1 and cancer: SHP2’s impact extends to myeloid cells, where its interaction with the PD-1-SHP2 axis affects GM-CSF-mediated protein phosphorylation, influencing myeloid differentiation and potentially offering opportunities for cancer immunotherapy [9].